Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Digestive Disorders Clear all
Completed Phase 3 Interventional

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00058149
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Aurora, Colorado + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

NCT06916078
View directory record Official record
Conditions
Liver Dysfunction, Healthy
Interventions
Lepodisiran
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Terminated Phase 2 Interventional

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

NCT00116389
View directory record Official record
Conditions
Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
Interventions
talabostat mesylate tablets, gemcitabine
Drug
Lead sponsor
Point Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Florence, Alabama • Muscle Shoals, Alabama • Hartford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2007 · Synced Sep 4, 2026, 7:06 AM EDT
Not listed Phase 2 Interventional

Secretin for Acute Pancreatitis

NCT03686618
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 4, 2026, 7:06 AM EDT
Active, not recruiting Not applicable Interventional

The BD Liverty™ TIPS Stent Graft Study

NCT05711316
View directory record Official record
Conditions
Portal Hypertension, TIPS
Interventions
BD Liverty™ TIPS Stent Graft
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

NCT03085004
View directory record Official record
Conditions
Pancreatic Cyst, EUS-FNA
Interventions
Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Not applicable Interventional

Optimizing Kidney Transplant Informed Consent

NCT01859884
View directory record Official record
Conditions
End-stage Kidney Disease
Interventions
Inform Me: web-based education tool
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Not applicable Interventional Results available

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NCT00961233
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
inhaled/swallowed budesonide, viscous/swallowed budesonide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Expanding the Pool in Lung Transplantation

NCT03377478
View directory record Official record
Conditions
Hepatitis C, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Pablo Sanchez
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 4, 2026, 7:06 AM EDT
Completed No phase listed Observational

Review of Infant Oral Feeding and Skills

NCT06736743
View directory record Official record
Conditions
Nutrition Disorders, Gastrointestinal Disease, Deglutition Disorder, Feeding Difficulties, Swallowing Difficulties, Humans, Cohort Studies, Infant, Newborn, Infant, Premature, Nutrition, Pediatric Feeding Disorder, Chronic, Retrospective Studies, Breastfeeding, Mental Health Wellness, Intensive Care Units, Neonatal, Bottle Feeding
Interventions
SMART Tool for Feeding Skill Assessment
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Weeks to 42 Weeks
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525
View directory record Official record
Conditions
Hepatitis C
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Sarasota, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

NCT01707225
View directory record Official record
Conditions
Gastrointestinal Bleeding
Interventions
Octreotide LAR Depot
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 4, 2026, 7:06 AM EDT
Completed No phase listed Observational

Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

NCT00304876
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

NCT00075504
View directory record Official record
Conditions
Stage II Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer
Interventions
triapine, gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 4, 2026, 7:06 AM EDT
Completed No phase listed Observational

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452
View directory record Official record
Conditions
Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions
oCRH
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
1,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Recruiting Phase 1 Interventional

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

NCT05285358
View directory record Official record
Conditions
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

NCT03798626
View directory record Official record
Conditions
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Interventions
Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

NCT00635089
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
reslizumab
Drug
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 4, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

L-Menthol Injection as a Novel Technique During Colonoscopy

NCT02588248
View directory record Official record
Conditions
Colonic Polyps, Colon Cancer
Interventions
Peppermint Oil, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 4, 2026, 7:06 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

NCT06948448
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab, Leucovorin
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management

NCT06068426
View directory record Official record
Conditions
Chronic Pancreatitis, Acute Recurrent Pancreatitis
Interventions
Transabdominal ultrasound Shear wave elastography
Diagnostic Test
Lead sponsor
David Vitale MD
Other
Eligibility
0 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Not applicable Interventional

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685
View directory record Official record
Conditions
Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions
DiNaMo Study App, Placebo App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 4, 2026, 7:06 AM EDT
Completed Not applicable Interventional Results available

Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients

NCT02245217
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PET/CT scan to assess treatment efficacy
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 4, 2026, 7:06 AM EDT